Urothelial Carcinoma Clinical Trial Pipeline Expands As 40+ Pharma Companies Progress 50+ Novel Therapies Toward Market Entry, Finds Delveinsight Janssen Research And Development, Medpacto

(MENAFN- GetNews)


"Urothelial Carcinoma – Pipeline Insight, 2026"DelveInsight's "Urothelial Carcinoma – Pipeline Insight, 2026" report provides comprehensive insights about 40+ companies, such as Janssen Research and Development, MedPacto, AstraZeneca, QED Therapeutics, Inovio Pharmaceuticals, Abbisko Therapeutics, Bayer, 4D pharma, RemeGen, Infinity Pharmaceuticals, Kyowa Kirin, Ikena Oncology, Vyriad, Seagen, Pfizer, Incyte Corporation, Prestige BioPharma, TARIS Biomedical and others, developing pipeline drugs in the Urothelial Carcinoma pipeline landscape

DelveInsight's " Urothelial Carcinoma – Pipeline Insight, 2026 " report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in the Urothelial Carcinoma pipeline landscape. It covers the Urothelial Carcinoma pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.

Explore the latest breakthroughs in the Urothelial Carcinoma treatment landscape. Learn more about the evolving Urothelial Carcinoma pipeline today @

Key Takeaways from the Urothelial Carcinoma Pipeline Report

• DelveInsight's Urothelial Carcinoma Pipeline Insight report depicts a robust space with 40+ active players working to develop 50+ pipeline therapies for Urothelial Carcinoma treatment.

• The most advanced pipeline candidate in Phase III clinical development is being progressed by Janssen Research and Development.

• Pemazyre (pemigatinib) by Incyte Corporation is a potent, selective, oral inhibitor of FGFR isoforms 1, 2 and 3, demonstrating selective pharmacologic activity against cancer cells with FGFR alterations, and is being evaluated in Urothelial Carcinoma.

• Cetrelimab by Janssen Research and Development is an investigational PD-1 monoclonal antibody being studied in the treatment of bladder cancer as a combination treatment.

• The leading Urothelial Carcinoma companies include Janssen Research and Development, MedPacto, AstraZeneca, Helsinn/QED Therapeutics, Inovio Pharmaceuticals, Abbisko Therapeutics, Bayer, 4D pharma plc, RemeGen, Infinity Pharmaceuticals, Kyowa Kirin, Inc., Ikena Oncology, Vyriad, Seagen, Pfizer, Incyte Corporation, Prestige BioPharma, TARIS Biomedical and others.

• Promising Urothelial Carcinoma therapies include Pemazyre (pemigatinib), Cetrelimab, Vactosertib, MV NIS and others.

Download for updates and the latest revolution in Urothelial Carcinoma care @ Urothelial Carcinoma Pipeline Report

Urothelial Carcinoma Emerging Drugs Profile

. Pemazyre (pemigatinib): Incyte Corporation

Pemazyre (pemigatinib) is a kinase inhibitor indicated in the United States for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. In Japan, Pemazyre is approved for the treatment of patients with unresectable biliary tract cancer (BTC) with an FGFR2 fusion gene, worsening after cancer chemotherapy. Pemazyre is a potent, selective, oral inhibitor of FGFR isoforms 1, 2 and 3 which, in preclinical studies, has demonstrated selective pharmacologic activity against cancer cells with FGFR alterations. The drug is currently being evaluated in clinical studies for Urothelial Carcinoma.

. Cetrelimab: Janssen Research and Development

Cetrelimab is a Janssen discovered and developed investigational programmed cell death receptor-1 (PD-1) monoclonal antibody being studied in the treatment of bladder cancer, prostate cancer, and multiple myeloma as a combination treatment. Cetrelimab is also being evaluated in multiple combination regimens across the Janssen oncology portfolio. It is the most advanced pipeline candidate in the Urothelial Carcinoma space and is currently in Phase III clinical development.

For more information on the Urothelial Carcinoma Emerging Drugs Profile, download DelveInsight's comprehensive Urothelial Carcinoma Pipeline Insight report.

The Urothelial Carcinoma Pipeline Report Provides

• Detailed insights about companies developing therapies for Urothelial Carcinoma, with aggregate therapies developed by each company.

• Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Urothelial Carcinoma treatment.

• Urothelial Carcinoma companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Urothelial Carcinoma drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company–company and company–academia), licensing agreements, and financing details for future advancement of the Urothelial Carcinoma market.

Learn more about Urothelial Carcinoma Drugs opportunities in our comprehensive Urothelial Carcinoma pipeline report @ Urothelial Carcinoma Unmet Needs

Urothelial Carcinoma Companies

There are 40+ key companies, such as Janssen Research and Development, MedPacto, AstraZeneca, Helsinn/QED Therapeutics, Inovio Pharmaceuticals, Abbisko Therapeutics, Bayer, 4D pharma plc, RemeGen, Infinity Pharmaceuticals, Kyowa Kirin, Inc., Ikena Oncology, Vyriad, Seagen, Pfizer, Incyte Corporation, Prestige BioPharma, TARIS Biomedical and others, developing therapies for Urothelial Carcinoma, with Janssen Research and Development having its Urothelial Carcinoma drug candidate in the most advanced Phase III stage.

DelveInsight's Urothelial Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

• Intranasal

• Intrathecal

• Intravenous

• Oral

• Oral/Intravenous

• Parenteral

• Subcutaneous

• Subcutaneous/Intramuscular

• Transdermal

Urothelial Carcinoma products have been categorized under various Molecule types such as:

• Antisense oligonucleotide

• Gene therapy

• Hormones

• Neuropeptides

• Oligonucleotides

• Small Molecule

• Triglyceride

Discover the latest advancements in Urothelial Carcinoma treatment by visiting our website. Stay informed @ Urothelial Carcinoma Market Drivers and Barriers, and Future Perspectives

Scope of the Urothelial Carcinoma Pipeline Report

• Coverage: Global

• Urothelial Carcinoma companies: Janssen Research and Development, MedPacto, AstraZeneca, Helsinn/QED Therapeutics, Inovio Pharmaceuticals, Abbisko Therapeutics, Bayer, 4D pharma plc, RemeGen, Infinity Pharmaceuticals, Kyowa Kirin, Inc., Ikena Oncology, Vyriad, Seagen, Pfizer, Incyte Corporation, Prestige BioPharma, TARIS Biomedical and others

• Urothelial Carcinoma Therapies: Pemazyre (pemigatinib), Cetrelimab, Vactosertib, MV NIS and others

• Urothelial Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

• Urothelial Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Table of Contents

Introduction

Executive Summary

Urothelial Carcinoma: Overview

Pipeline Therapeutics

Therapeutic Assessment

Urothelial Carcinoma – DelveInsight's Analytical Perspective

Late Stage Products (Phase III)

Mid Stage Products (Phase II)

Early Stage Products (Phase I)

Preclinical and Discovery Stage Products

Inactive Products

Urothelial Carcinoma Key Companies

Urothelial Carcinoma Key Products

Urothelial Carcinoma Unmet Needs

Urothelial Carcinoma Market Drivers and Barriers

Urothelial Carcinoma Future Perspectives and Conclusion

Urothelial Carcinoma Analyst Views

Appendix

MENAFN30032026003238003268ID1110921194